Orris

I want to learn everything related to mao inhibitors and tca …i want to learn history, pharmacokinetics dynamics, indications , guidelines, side effect profile, contraindications, recent advances , dose and administration, formulation, special population, discontinuation, toxicity

Reading File
Finding Sources
Finding Sources
Searching PubMed

monoamine oxidase inhibitors AND tricyclic antidepressants

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Searching PubMed

MAO inhibitors treatment resistant depression

Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Searching the Web

MAO inhibitors TCA recent advances 2024 2025 new indications clinical trials

Reading File
Reading File
This is a comprehensive guide covering everything you asked about. Here's a brief map of what's covered:
MAOIs (Part I):
  • Historical discovery from iproniazid (TB drug, 1952) through selegiline
  • Full biochemistry of MAO-A vs MAO-B enzyme subtypes
  • Classification table (irreversible/reversible × selective/non-selective)
  • Pharmacokinetics of each agent individually (phenelzine, isocarboxazid, tranylcypromine, oral/transdermal selegiline)
  • Detailed dosing table with formulations
  • Indications (FDA-approved + off-label, especially treatment-resistant depression and atypical depression)
  • Complete side effect profile (CV, CNS, metabolic, hepatic)
  • Drug and food interactions with mechanisms (tyramine reaction, serotonin syndrome)
  • Contraindications, special populations, discontinuation, and overdose management
TCAs (Part II):
  • History from imipramine (1957, Kuhn) through the full class development
  • Chemistry (tertiary amines vs secondary amines vs tetracyclics)
  • Multi-receptor pharmacodynamics table with clinical correlates
  • Detailed pharmacokinetics including P-glycoprotein, CYP2D6 genetics, and TDM targets
  • Full dosing table for all 9+ agents
  • Side effects by system (anticholinergic, cardiac, CNS, metabolic)
  • Overdose management with sodium bicarbonate as the key antidote
  • All special populations including pregnancy, elderly (Beers Criteria), children
Recent Advances (Part IV): Major 2024–2026 literature including the MAOI rehabilitation movement, network meta-analyses confirming MAOI efficacy, transdermal delivery advances, and pharmacogenomics.
This is a shared conversation. Sign in to Orris to start your own chat.